ABSTRACT
INTRODUCTION In contrast to small molecular weight drugs (SMD), the development of in vitroin vivo correlations (IVIVCs) for monoclonal antibody (mAb) therapeutics is still in its infancy. High-throughput in vitro assays with established IVIVC that currently exist for SMD have not been so strongly pursued for antibody (Ab) therapeutics, reflecting to a certain degree the substantially lower attrition rate and the associated lower numbers of potential clinical mAb candidates. This chapter represents one of the first attempts at summarizing the available data correlating preclinical in vitro and in vivo data of mAbs.
